Highbridge Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Highbridge Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-833	Closed	-$287K	–	797
2018 Q2	$287K	Buy	+833	New	+$261K	0.01%	717
2018 Q1	–	Sell	-21,455	Closed	-$7.46M	–	1624
2017 Q4	$8.07M	Buy	+21,455	New	+$8.69M	0.14%	194
2017 Q1	–	Sell	-882	Closed	-$323K	–	1656
2016 Q4	$323K	Buy	+882	New	+$335K	0.01%	944
2016 Q3	–	Sell	-13,893	Closed	-$4.85M	–	1624
2016 Q2	$4.85M	Buy	13,893 +12,557	+940%	+$4.84M	0.08%	260
2016 Q1	$481K	Buy	+1,336	New	+$551K	0.01%	993
2015 Q4	–	Sell	-3,266	Closed	-$1.52M	–	1757
2015 Q3	$1.52M	Buy	+3,266	New	+$1.75M	0.02%	631
2014 Q3	–	Sell	-14,931	Closed	-$4.22M	–	1332
2014 Q2	$4.22M	Buy	+14,931	New	+$4.43M	0.05%	283
2014 Q1	–	Sell	-1,400	Closed	-$385K	–	1216
2013 Q4	$385K	Buy	+1,400	New	+$403K	﹤0.01%	755
2013 Q3	–	Sell	-33,367	Closed	-$7.5M	–	1479
2013 Q2	$7.5M	Buy	+33,367	New	+$7.77M	0.07%	266

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Highbridge Capital Management's REGN Position: Q3 2018 in Review

Highbridge Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2018, closing a stake of 833 shares — an estimated $287K sold.

Highbridge Capital Management first reported a position in REGN in Q2 2013 and held it in 9 quarters. The position peaked at $8.07M in Q4 2017. 644 funds tracked by Wall St. Rank hold REGN as of Q3 2018.

Highbridge Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Highbridge Capital Management sold 833 Regeneron Pharmaceuticals shares in Q3 2018, an estimated $287K.
Highbridge Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 9 quarters.
Highbridge Capital Management's Regeneron Pharmaceuticals position peaked at $8.07M in Q4 2017.
644 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2018.

Based on Highbridge Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.